DR. ROBERT SEGAL, MD
Osteopathic Medicine in Gwynedd Valley, PA
License number
Pennsylvania MD052562L
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
106 Hillcrest Ln, Gwynedd Valley, PA 19437
Phone
(267) 237-7576
(215) 628-3416 (Fax)
(215) 628-3416 (Fax)
Personal information
See more information about ROBERT SEGAL at radaris.comName
Address
Phone
676 W Rolling Rd, Springfield, PA 19064
114 W Porter St, Philadelphia, PA 19148
137 Sigel St, Philadelphia, PA 19148
163 Pilgrim Dr, Boalsburg, PA 16827
1130 Red Rose Ln, Villanova, PA 19085
Professional information
Pulmonary Surfactant Formulations And Methods For Promoting Mucus Clearance
US Patent:
8221772, Jul 17, 2012
Filed:
Sep 19, 2007
Appl. No.:
11/901866
Inventors:
Robert Segal - Gwynedd Valley PA, US
Thomas Hofmann - Doylestown PA, US
Robert J. Capetola - Doylestown PA, US
Thomas Hofmann - Doylestown PA, US
Robert J. Capetola - Doylestown PA, US
Assignee:
Discovery Laboratories Inc. - Warrington PA
International Classification:
A61K 9/12, A61K 38/03, A61K 38/16
US Classification:
424400, 424450, 514 17, 514 18, 514 155
Abstract:
Methods and compositions to enhance mucus clearance and to treat pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize compositions including synthetic pulmonary surfactants having one or more phospholipids and a synthetic polypeptide, administered alone or combined with hyperosmotic agents, to patients in an amount effective to enhance mucus clearance.
Method For Decreasing Qt Dispersion Or Inhibiting The Progression Of Qt Dispersion With An Angiotensin Ii Receptor Antagonist
US Patent:
6300356, Oct 9, 2001
Filed:
Aug 10, 2000
Appl. No.:
9/601938
Inventors:
Robert Segal - Gwynedd Valley PA
Paul J. Robinson - Hertfordshire, GB
Lawrence I. Deckelbaum - Gladwyne PA
Paul J. Robinson - Hertfordshire, GB
Lawrence I. Deckelbaum - Gladwyne PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31415, A61N 1378
US Classification:
514381
Abstract:
Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in die risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.
Method For Reducing Mortality With An Angiotensin Ii Antagonist
US Patent:
6201002, Mar 13, 2001
Filed:
Jan 6, 1998
Appl. No.:
9/003159
Inventors:
Polly A. Beere - Lahaska PA
Paul I. Chang - Doylestown PA
Bertram Pitt - Ann Arbor MI
Eva J. Rucinska - Blue Bell PA
Robert Segal - Gwynedd Valley PA
Divakar Sharma - Hatfield PA
Duane B. Snavely - Chalfont PA
Paul I. Chang - Doylestown PA
Bertram Pitt - Ann Arbor MI
Eva J. Rucinska - Blue Bell PA
Robert Segal - Gwynedd Valley PA
Divakar Sharma - Hatfield PA
Duane B. Snavely - Chalfont PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A01N 4350
US Classification:
514397
Abstract:
Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.
Surfactant Treatment Regimen
US Patent:
7541331, Jun 2, 2009
Filed:
Jan 6, 2006
Appl. No.:
11/326885
Inventors:
Anthony Killian - Easton PA, US
Christopher Schaber - Columbus NJ, US
Robert Segal - Gwynedd Valley PA, US
Carlos Guardia - Philadelphia PA, US
Christopher Schaber - Columbus NJ, US
Robert Segal - Gwynedd Valley PA, US
Carlos Guardia - Philadelphia PA, US
Assignee:
Discovery Laboratories, Inc. - Warrington PA
International Classification:
A01N 37/18, A61K 38/00, A01N 33/00
US Classification:
514 2, 514 12, 514 13, 514579
Abstract:
Regimens for the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia are disclosed.